ReviewCritical care (London, England)2026
AKI as a systemic syndrome and its impact on other organ systems.
Review in Critical care (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute kidney injury (AKI) affects approximately 15% of all hospitalized individuals and nearly half of those admitted to intensive care units and is increasingly recognized as a systemic syndrome whose consequences extend well beyond structural and functional changes confined to the kidney. Experimental studies highlight the role of inflammation and accumulation of metabolites as pivotal drivers in the cross-talk between the kidneys and distant organ systems during AKI. Whereas clinical data reveals an association between AKI and non-renal organ dysfunctions and complications. This review outlines the pathophysiological mechanisms underlying AKI-associated remote organ dysfunction, focusing on five key organ systems: the lungs, the brain, the heart, the liver and the immune system. We discuss the direct consequences of reduced kidney function alongside the repercussions of the inflammatory cascade triggered by kidney cell injury and the resulting clinical implications. Recognizing that multi-organ failure significantly influences patients' morbidity and mortality, identifying specific pathways of organ cross-talk is essential to optimize clinical management. Finally, we evaluate novel endpoints for future AKI trials. Given that traditional long-term metrics, such as Major Adverse Kidney Events (MAKE), present significant design challenges in non-enriched populations, we analyze alternative and surrogate outcomes, including those directly related to the remote organ complications of AKI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.